One Step Closer to the Clinic
Twist Biopharma’s antibody experts have discovered and vetted an array of lead antibodies against high-value targets, saving you the trouble of launching your discovery and optimization projects and accelerating your journey from bench to bedside.
De-Risked for Common Downstream Liabilities
Potential for First-in-Class Licensing
Evaluated by Our Experts
See Which Therapeutic Targets We’ve Unlocked
Best-in-Class Therapeutics Start With a Best-in-Class Discovery Platform
Our unique, high-quality DNA writing platform allows us to design diverse antibody variants, with base-by-base precision. Using that as our foundation, we’ve built a best-in-class discovery platform, our library of libraries, which served as the starting point for our antibody leads.
Learn More About Our LibrariesChallenging Targets Unlocked by Our Experts
Our library of libraries and internal expertise has enabled the discovery and selection of leads against challenging drug targets, like GLP-1R and ADORA2A. Each discovery project was led by our internal team of experts, with over 50 years of combined experience in therapeutic antibody development.
Watch the Webinar
Developing Therapeutics Against Virtually Any Target with New Antibody Libraries
Brochure
Webinar
